2025年5月20日 周二
Home > Archive>Volume 29, Issue 9, 2021 >825-828
PDF HTML XML Export Cite reminder
Research progress of myocardial injury associated with novel coronavirus infection
Author:
Affiliation:

1.Zunyi Medical University, Zunyi, Guizhou 563003, China;2.Department of Cardiology, The Second People's Hospital of Chengdu Affiliated to Zunyi Medical University, Chengdu, Sichuan 610017, China)

Clc Number:

R5

  • Article
    • | |
  • Metrics
    • |
  • Reference [26]
    • | | | |
  • Comments
    Abstract:

    Since the discovery of pneumonia infected by the new coronavirus (SARS-CoV-2), it has brought great pressure to China's public health cause. With the in-depth study of the new coronavirus, it was found that SARS-CoV-2 infection is closely related to myocardial injury in patients. More and more attention has been paid to the myocardial damage caused by the new coronavirus in clinic. This article reviews the possible pathogenesis, diagnosis, and treatment of myocardial injury associated with novel coronavirus infection, with a view to providing assistance to the treatment of SARS-CoV-2 infection in patients with cardiovascular disease.

    Reference
    [1] 中华预防医学会新型冠状病毒肺炎防控专家组.新型冠状病毒肺炎流行病学特征的最新认识.中华流行病学杂志, 0,1(2):139-144.
    [2] 姜志胜.应高度关注新型冠状病毒肺炎合并的心血管系统损伤.中国动脉硬化杂志, 0,8(4):277-280.
    [3] 郭颖, 裴作为, 朱火兰, 等.新型冠状病毒肺炎相关心肌损伤的临床管理专家建议(第一版).中国循环杂志, 0,5(4):326-330.
    [4] GAO Q, HU Y, DAI Z, et al.The epidemiological characteristics of 2019 novel coronavirus diseases (COVID-19) in Jingmen, Hubei, China.Medicine (Baltimore), 0,9(23):e20605.
    [5] CHEN L, LI X, CHEN M, et al.The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2.Cardiovasc Res, 0,6(6):1097-1100.
    [6] PADRO T, MANFRINI O, BUGIARDINI R, et al.ESC working group on coronary pathophysiology and microcirculation position paper on coronary microvascular dysfunction in cardiovascular disease.Cardiovasc Res, 0,6(4):741-755.
    [7] 施冰, 李俊峡.新型冠状病毒肺炎与心肌损伤.中国循证心血管医学杂志, 0,2(2):158-159.
    [8] ZHONG J, BASU R, GUO D, et al.Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.Circulation, 0,2(7):717-728.
    [9] CRACKOWER M A, SARAO R, OUDIT G Y, et al.Angiotensin-converting enzyme 2 is an essential regulator of heart function.Nature, 2,7(6891):822-828.
    [10] MARKUS H, KLEINE-WEBER H, SCHROEDER S, et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.Cell, 0,1(2):271-280.e8.
    [11] GHEBLAWI M, WANG K, VIVEIROS A, et al.Angiotensin-converting enzyme 2:SARS-CoV-2 receptor and regulator of the renin-angiotensin system:celebrating the 20th anniversary of the discovery of ACE2.Circ Res, 0,6(10):1456-1474.
    [12] SIMOES E SILVA A C, TEIXEIRA M M.ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis.Pharmacol Res, 6,7:154-162.
    [13] BUCKLEY L F, CHENG J, DESAI A.Cardiovascular pharmacology in the time of COVID-19:a focus on Angiotensin-Converting enzyme 2.J Cardiovasc Pharmacol, 0,5(6):526-529.
    [14] LIU Y, YAN L M, WAN L, et al.Viral dynamics in mild and severe cases of COVID-19.Lancet Infect Dis, 0,0(6):656-657.
    [15] 罗晶晶, 董念国, 史嘉玮.新型冠状病毒感染相关心脏损害的机制探讨.临床心血管病杂志, 0,6(4):307-310.
    [16] 吴小平, 王培利, 王承龙.新型冠状病毒肺炎的心脏损害及对策探析.中国中西医结合杂志, 0,0(3):275-278.
    [17] HUANG C, WANG Y, LI X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet, 0,5(1223):497-506.
    [18] ZHU Z, CAI T, FAN L, et al.Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019.Int J Infect Dis, 0,5(20):332-339.
    [19] LI H, CHEN K, LIU M, et al.The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia.J Infect, 0,1(1):115-120.
    [20] 李国华, 李玲, 何敏, 等.多种炎症指标联合淋巴细胞亚群在COVID-19不同临床分型的临床诊断价值分析[J/OL].重庆医科大学学报, 0,5(7):971-975.
    [21] DENG Q, HU B, ZHANG Y, et al.Suspected myocardial injury in patients with COVID-19:evidence from front-line clinical observation in Wuhan, China.Int J Cardiol, 0,1(20):116-121.
    [22] 张玉, 陈孝, 张毕奎, 等.新型冠状病毒肺炎临床合理用药专家共识.中国医院药学杂志, 0,0(6):593-605.
    [23] ULRICH H, PILLAT M M.CD147 as a target for COVID-19 treatment:suggested effects of azithromycin and stem cell engagement.Stem Cell Rev Rep, 0,6(3):434-440.
    [24] JAKOVAC H.COVID-19 and vitamin D-Is there a Link and an opportunity for intervention?.Am J Physiol Endocrinol Metab, 0,8(5):E589.
    [25] LUO P, LIU D, LI J.Pharmacological perspective:glycyrrhizin May be an efficacious therapeutic agent for COVID-19.Int J Antimicrob Agents, 0,5(6):105995.
    [26] MAIESE K.The mechanistic target of rapamycin (mTOR):novel considerations as an antiviral treatment.Curr Neurovasc Res, 0,7(3):332-337.
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

XIE Jianhua, LIAO Chongmi, HUANG Hai, ZHU Kunhao, XU Shengsheng, LIU Jianxiong. Research progress of myocardial injury associated with novel coronavirus infection[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2021,29(9):825-828.

Copy
Share
Article Metrics
  • Abstract:1014
  • PDF: 594
  • HTML: 0
  • Cited by: 0
History
  • Received:May 15,2020
  • Revised:August 17,2020
  • Online: August 10,2021
Article QR Code

You are the 46544 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025